Literature DB >> 2805024

Effect of cisapride on excessive regurgitation in infants.

M Van Eygen1, H Van Ravensteyn.   

Abstract

The relevance of the upper gastrointestinal motility-stimulating effects of cisapride for the treatment of excessive regurgitation and vomiting in infants was studied in 137 patients aged less than 1 year. They were treated with placebo or with cisapride, 0.1 to 0.2 mg/kg three times daily, for up to four weeks. In a dose-dependent fashion, cisapride significantly reduced the frequency and severity of regurgitation: after four weeks of treatment at 0.15 to 0.2 mg/kg, only about 20% of infants still had moderate or severe regurgitation, compared with about two thirds of those treated with placebo. Although only a few patients were followed up, the duration of treatment (four weeks) appeared to be long enough to minimize relapse. Side effects were limited to phenomena indicative of stimulated bowel motility.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805024

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

1.  Varicella: to vaccinate or not to vaccinate?

Authors:  A Gershon
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

2.  Diagnosis and treatment of gastroesophageal reflux disease in infants and children.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

3.  The risks and benefits of cisapride in premature neonates, infants, and children.

Authors:  A Lander; A Desai
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

Review 4.  Cisapride treatment for gastro-oesophageal reflux in children.

Authors:  Suzanna Maclennan; Cristina Augood; Lucinda Cash-Gibson; Stuart Logan; Ruth E Gilbert
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 5.  Efficacy and tolerability of cisapride in children.

Authors:  Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

8.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.